Objectives: Anti-programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) immunotherapy has demonstrated success in the treatment of advanced NSCLC. Recently, PD-1/PD-L1 blockade also has demonstrated interesting results in small trials of neoadjuvant treatment in stage IB to IIIA NSCLC. In addition, several clinical trials using anti-PD-1/PD-L1 immunotherapy as an adjuvant or neoadjuvant treatment in patients with resectable stage NSCLC are ongoing. However, few analyses of anti-PD-1/
PD-L1 immunotherapy-related biomarkers in early-stage squamous cell lung carcinoma (SqCLC) have been reported. In this study, we evaluated PD-L1 protein expression, tumor mutation burden, and expression of an immune gene signature in early-stage SqCLC, providing data for identifying the potential role for patients with anti-PD-1/ PD-L1 treatment in early-stage SqCLC.
Methods: A total of 255 specimens from patients with early-stage SqCLC were identified within participating centers of the Strategic Partnering to Evaluate Cancer Signatures program. PD-L1 protein expression by immunohistochemistry was evaluated by using the Dako PD-L1 22C3 pharmDx kit on the Dako Link 48 auto-stainer (Dako, Carpinteria, CA). Tumor mutation burden (TMB) was calculated on the basis of data from targeted genome sequencing. The T-effector and interferon gamma (IFN-g) gene signature was determined from Affymetrix gene chip data (Affymetrix, Santa Clara, CA) from frozen specimens.
Results:
The prevalence of PD-L1 expression was 9.8% at a tumor proportion score cutoff of at least 50%. PD-L1 mRNA and programmed cell death 1 ligand 2 mRNA positively correlated with PD-L1 protein expression on tumor cells (TCs) and tumor-infiltrating immune cells. PD-L1 protein expression on tumor-infiltrating immune cells was correlated with the T-effector and IFN-g gene signature (p < 0.001), but not with TMB. For TCs, all of these biomarkers were independent of each other and neither PD-L1 protein expression, TMB, or T-effector and IFN-g gene signatures were independently prognostic for patient outcomes.
Conclusions: Evaluation of PD-L1 expression, TMB, and T-effector and IFN-g gene signatures in the cohort with early-stage SqCLC found them to be independent of each other, and none was associated with overall survival. Our results also support the hypothesis that PD-L1 expression is regulated by an intrinsic mechanism on TCs and an adaptive mechanism on immune cells.
Introduction
NSCLC represents 87% of all lung cancers, and of these, approximately one-third are squamous cell carcinoma (SqCLC). 1 Several therapy options have become available for patients with adenocarcinoma, but there has been little progress for patients with SqCLC. Patients with early-stage SqCLC (stages I-IIIA) are treated by surgery with curative intent after which adjuvant chemotherapy following surgery is offered to those patients with stage IB (>4 cm), II, or IIIA disease.
Postoperative adjuvant chemotherapy improves survival to a modest degree in stage II to III NSCLC, 2,3 but it is not recommended for stage I disease, even though patients with stage IA and IB NSCLC experience 5-year survival rates of only 82% and 66%, respectively, after complete surgical resection. 4 On the basis of recent success obtained with immunotherapy for several types of tumors, including advanced NSCLC, there is renewed hope for treatment of SqCLC. In several clinical trials, immune checkpoint inhibitors have been shown to be superior to chemotherapy in the frontline and second-line settings (Fig. 1) . [5] [6] [7] [8] [9] Increasingly, clinical data have shown that the expression of programmed death ligand 1 (PD-L1) in patient tumors predicts the likelihood of a positive response to anti-programmed cell death 1 (PD-1)/PD-L1 immunotherapy.
10-13 PD-L1 protein expression determined by immunohistochemistry (IHC) remains the most frequently used biomarker for predicting clinical benefit from anti-PD-1/PD-L1 therapies, as has been demonstrated in many clinical trials. 5, 10, [13] [14] [15] Additionally, tumor mutation burden (TMB) may further help predict response. By using a whole-exome sequence assay, Rizvi et al. recently demonstrated that treatment efficacy is associated with higher mutation burden in advanced NSCLC tumors. 16 In addition, Gandara et al. found that not only is TMB in tissue correlated with the efficacy in first-line immunotherapy-treated NSCLC, but TMB in blood measured from cell-free DNA in patients' plasma may predict clinical efficacy in NSCLC treated with immunotherapy as second-line care. 17 TMB has also been reported to enhance the predictive power of PD-L1 IHC for selecting patients who benefit from first-line therapy with nivolumab. 8 Several clinical trials in advanced melanoma have provided evidence that gene expression profiling can indeed be a useful predictive biomarker. [18] [19] [20] Immune gene signatures, especially those induced by interferon gamma (IFN-g), may serve as robust biomarkers for predicting the clinical benefit of anti-PD-1/PD-L1 therapies, a theory of which has been supported by PD-L1 expression data. In the POPLAR study, a T-effector and IFN-g gene signature was identified by eight genes that were previously associated with activated T cells, immune cytolytic activity, and IFN-g expression. 11, [21] [22] [23] [24] Patients with preexisting immunity, defined by high T-effector and IFN-g-associated gene expression, had improved overall survival with atezolizumab. 11 However, research on the expression of PD-L1 and other immunotherapy-related biomarkers in early-stage SqCLC is limited. In this study, we evaluated PD-L1 protein expression level in 255 early-stage SqCLCs by IHC. We quantitatively assessed the TMB with correlation to PD-L1 protein expression and clinical characteristics. Immune gene expression was analyzed by mRNA profiling by using an Affymetrix (Santa Clara, CA)-based gene expression platform. This study analyzed anti-PD-1/PD-L1 immunotherapy-related biomarkers in a large cohort of patients with early-stage SqCLC in association with clinical characteristics.
Methods

Patient Population
A total of 255 patient specimens were collected from six centers (University of Colorado, University of Michigan, Washington University, Duke University, Brigham and Women's Hospital, and Princess Margaret Cancer Center) participating in the Strategic Partnering to Evaluate Cancer Signatures program. Each center identified approximately 50 samples from resected patients with stage I to II SqCLC who had either (1) died from lung cancer or (2) had a minimum of 3 years of follow-up without documented disease recurrence. None of the patients had received adjuvant, neoadjuvant, or radiotherapy before surgery, with the exception of two patients who had received adjuvant therapy. All primary diagnoses were reviewed by experienced pathologists at each site according to the WHO nomenclature for squamous carcinoma. 25 
TMB
As part of an independent study (manuscript in preparation), 199 of the 255 patients' tumors were subject to targeted exome sequencing using a capture panel representing 1537 cancer-related genes. Tumor DNA was isolated from paraffin section slides, and, where necessary, macrodissected for areas of greater than 60% to 90% enriched tumor cellularity. Targeted capture sequencing was performed with sequence alignment and variant calling using the Genome Modeling System (GMS) pipeline. 26 To identify true somatic variant calls in the absence of paired, nonmalignant specimens, results were further filtered by using the variant reporting subsystem, which implements several additional user-defined filtering steps and annotates the resulting variants with information about their allele frequencies in the Single Nucleotide Polymorphism database, the 1000 Genomes Project, and the National Heart, Lung and Blood Institute database. Variants were required to have a minimum variant allele frequency of 10%, have a minimum coverage of 10Â, and be present strictly in the on-target regions. Any variants exceeding 0.01% in National Heart, Lung and Blood Institute European, African-American, or all data sets, or in the 1000 Genomes Project, were removed. An additional panel of 905 normal breast tissue samples was used as a germline filter. Variants that appeared in five or more samples from that data set were also removed. Finally, a subset of the Exome Aggregation Consortium data set was incorporated into the pipeline 27 to exclude other potential germline variants.
RNA Profiling
Frozen specimens were macrodissected to enrich for neoplastic tissue. RNA isolation, complementary RNA synthesis, and Affymetrix gene expression profiling were performed as described by Raponi et al. 28 After RNA isolation with Trizol (Invitrogen, Carlsbad, CA) and RNeasy column purification (Qiagen, Valencia, CA), RNA yield and purity were assessed by using Nanodrop, RNA integrity was determined with an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), and the concentration calculated by optical density 260 measurement. GeneChip quality was assessed by using the Affymetrix Microarray Suite and Mining Tools and recorded for each sample. CHP files were generated from CEL files and probe IDs for all genes retrieved. Spline quantile normalization was applied and analysis of variance was used to remove batch effects or outlier samples from various sites. A T-effector and IFN-g gene signature was defined by CD8a molecule gene (CD8A), granzyme A gene (GZMA), granzyme B gene (GZMB), interferon gamma gene (IFNG), eomesodermin gene (EOMES), C-X-C motif chemokine ligand 9 gene (CXCL9), C-X-C motif chemokine ligand 10 gene (CXCL10), and T-box 21gene (TBX21). 11 The high-biomarker group was defined as that with gene expression at or above the median level, and the low biomarker group was defined as that with gene expression below the median level as described in the POPLAR study. Expression of programmed death ligand 1 gene (PD-L1 [also known as CD274]) and expression of programmed death ligand 2 gene (PD-L2 [also known as PDCD1LG2]) were also evaluated.
Data and Statistical Analysis
To assess the association between clinical features and biomarkers, we used the two-sample t test for continuous variables and Fisher's exact test for categorical variables. The Pearson correlation coefficient was used to evaluate the correlation between two numerical biomarkers. To further assess the linear trend between ordinal variables, we used the Cochran-Mantel-Haenszel trend test. A log-rank test was used to test the group differences of survival time. All analyses were two sided with an alpha of 0.05 as the significance level. The p values were not adjusted for potential multiple comparisons owing to the exploratory nature of the study. All analyses were performed using SAS statistical software (version 9.4, SAS Institute, Inc., Cary, NC) or R software (R Foundation for Statistical Computing, Vienna, Austria).
Results
PD-L1 Protein Expression in Early-Stage SqCLC and Association with Clinical Characteristics
Samples were collected from 255 patients with earlystage SqCLC. The distribution of PD-L1 expression on TCs and TIICs at different cutoffs (on the basis of the published association of cutoff with clinical response to anti-PD-1 therapy) are shown in Tables 1 and 2 . The overlap of populations for level of PD-L1 protein expression on TCs and TIICs is shown in Figure 2 . Patients with coexpression of PD-L1 on both TCs and TIICs at high levels were few (4%). A linear trend association was found between PD-L1 protein expression on TCs and the expression on TIICs at a TPS cutoff of at least 5% only (p ¼ 0.036). PD-L1-positive staining on TCs at that cutoff had a higher PD-L1 staining on TIICs.
Of the cases of the 208 patients with clinical data, six were missing a TPS value. For 202 cases with both clinical and PD-L1 protein expression data, no significant association was observed between the PD-L1 protein expression in TCs and clinical characteristics (Table 3) or prognosis (Fig. 3A) .
Analysis also revealed a positive correlation between PD-L1 protein expression on TCs and PD-L1 mRNA level (p < 0.0001, r ¼ 0.62) and programmed death ligand 2 (PD-L2) mRNA expression (p < 0.0001, r ¼ 0.45). PD-L1 mRNA level correlated with PD-L2 mRNA (p < 0.0001, r ¼ 0.64) as well (Fig. 4) . Both PD-L1 mRNA level and PD-L2 mRNA level were linearly associated with PD-L1 protein expression on TIICs as well (both p ¼ 0.033).
TMB and Clinical Characteristics
TMB was evaluated in 199 specimens from patients with SqCLC. Preliminary quality filtering on somatic variation calls was performed to choose only on-target regions and those that met other quality thresholds (e.g., minimum coverage >10Â). Extensive additional mutational filtering on the output of the somatic variation pipeline using various data sets, such as 1000 (Fig. 3B ).
T-Effector and IFN-Ƴ Gene Signature Expression
The T-effector and IFN-g gene signature was used to evaluate the status of the tumor microenvironment for 208 patients. Eight genes that are associated with T-cell activation and IFN-g level were included in the panel. The z scores were calculated for each gene in the eightgene signature. The median of the averages of the eight genes' z scores were then used to dichotomize the patients at the median into high and low groups. The data did not reveal any correlation between the T-effector and IFN-g gene signature and clinical characteristics or prognosis (Supplementary Table 2 and Fig. 3C ).
Correlation among PD-L1 Protein Expression, TMB, and T-Effector and IFN-g Gene Signature
Of 153 patients who had data on all three biomarkers, 4.6% (seven of 153) showed high levels of all three biomarkers at a PD-L1 TPS cutoff of at least 50%. In addition, 15.7% of the patients (24 of 153) demonstrated negative expression for all three biomarkers (Fig. 5) . Neither PD-L1 expression on TCs nor PD-L1 expression on TIICs was associated with TMB. The data for TMB also did not correlate with the T-effector and IFN-g gene signature. Interestingly, a significant association (p < 0.001 [Cochran-Mantel-Haenszel trend test]) was observed between T-effector and IFN-g gene signature and PD-L1 expression on TIICs (Fig. 6 ). Higher T-effector and IFN-g gene signature scores were associated with higher PD-L1 expression on TIICs. We further explored the prognosis of patients with PD-L1 expression at a TPS cutoff of at least 50% on TCs and a high TMB. These patients did not significantly correlate with a worse prognosis than the others (Fig. 7) .
Discussion
Recently, anti-PD-1/PD-L1 immunotherapy has produced objective and often durable responses in approximately 20% of patients with previously treated NSCLC who were not selected on the basis of PDL-1 expression. Despite this low overall response rate, overall survival was superior to that with docetaxel chemotherapy for most patient subgroups, including those with squamous cancers. Furthermore, a modest proportion of patients achieved long-term survival, even for up to 2 years or more. 5, 11, 13, 14 Despite complete resection, recurrent disease develops within 5 years in 25% of patients with stage IA disease and 45% of those with stage IB disease. Adjuvant chemotherapy can improve survival moderately in stage II to III NSCLC. 29 The objective of our study was to perform a comprehensive analysis of potential immune biomarkers in early-stage SqCLC, examine the overlap and relationship of these biomarkers to each other, and evaluate their prognostic role in resected SqCLC.
At the present time, expression of PD-L1 determined by IHC remains the only validated biomarker that has demonstrated a strong correlation with response in most trials. However, there is variability in marker staining among the approved antibody tests. 30 In this study, we detected PD-L1 expression by IHC in the cohort with early-stage SqCLC by using the Dako 22C3 pharmDx kit, which has been approved by the U.S. Food and Drug Administration as the companion diagnostic for pembrolizumab. Both the International Association for the Study of Lung Cancer Blueprint study and National Comprehensive Cancer Network-Bristol-Myers Squibb comparison study aimed to evaluate the variability of current assays, including U.S. Food and Drug Administration-approved or laboratory-derived tests. 31, 32 Data from these studies showed that the Dako 22C3, Dako 28-8, E1L3N (Cell Signaling Technologies, Danvers, MA), and SP263 (Ventana Medical Systems, Tucson, AZ) assays were closely aligned on TC staining.
Our data demonstrate that the prevalence of PD-L1 expression on TCs in the cohort with early-stage SqCLC was 9.8% at a TPS cutoff of at least 50%. In comparison, data from clinical trials of pembrolizumab demonstrated a PD-L1 prevalence ranging from 20% to 30% in advanced NSCLC with use of the 22C3 antibody at the same cutoff. 7, 13, 15, 33, 34 However, in a study that enrolled 678 patients with stage I to III NSCLC and detected the prevalence of PD-L1 expression by using the 22C3 antibody found high PD-L1 expression in 7.4% of NSCLC cases and 8.1% of the SqCLCs at a TPS cutoff of at least 50%, 35 which was close to our result. Another study that enrolled 170 Chinese patients with stage I to III NSCLC reported a prevalence in PD-L1 expression of 15.8% in the SqCLC specimens with use of the same antibody at the same cutoff. 36 These data indicate that increased PD-L1 expression may be associated with tumor progression and advanced tumor stage. One theory is that of heterogeneity selection. According to this concept, TCs without PD-L1 expression at early-stage disease are eliminated by T cells, whereas TCs expressing PD-L1 escape from the immune response. As the tumor stage advances, more TCs express PD-L1 and have the ability to escape immune elimination. However, results from studies on the association of PD-L1 expression with the tumor stage in NSCLC or in lung adenocarcinoma alone are often not in agreement with regard to correlations of PD-L1 expression and tumor stage. 35, [37] [38] [39] Although there was no significant correlation between PD-L1 expression and tumor stage in our study of specimens from patients with early-stage SqCLC, this may have been due to the fact that most of the patients in our cohort were at stages I to II.
Tumors with a higher TMB have been hypothesized to have more neoantigens that can be recognized by the immune system in response to checkpoint inhibition. In 2015, Rizvi et al. 16 identified TMB as a promising predictive biomarker for NSCLC immunotherapy. In that single-arm study, assessment of somatic, nonsynonymous TMB in patients with NSCLC who received pembrolizumab was determined by using whole-exome sequencing, and it correlated with improved overall response rates, progression-free survival, and durable clinical benefit. Recently, several additional studies evaluated TMB by next-generation sequencing (NGS) and correlated the results with immunotherapy response. Rizvi et al. used the Memorial Sloan KetteringIntegrated Mutation Profiling of Actionable Cancer Targets platform to evaluate TMB in 240 patients with advanced NSCLC and showed a median TMB of 7.4 single-nucleotide variants per Mb. 40 In a study of 454 patients treated with atezolizumab and assessed for TMB from a 315-gene NGS panel, Kowanetz et al. reported a median mutational load of 9.9 per Mb and classified higher than the 75th percentile as a high TMB. 41 In our study, the median TMB was determined to be 35 per Mb, which unlike in other studies, includes both synonymous and nonsynonymous variants and insertion and/or deletions. Given the differences in NGS gene panel content, variant filtering methods, and definitions of "high" TMB thresholds, it is difficult to compare TMB results across studies. The immunogenicity of specific mutations may play a more important role in neoantigen recognition by the immune system. In the case of a nonimmunogenic mutation, the altered peptide may not present the altered amino acid sequence for recognition or may bind poorly to the major histocompatibility complex class I molecule. The altered amino acids might also not be accessible to the Tcell antigen receptor. In an immunogenic mutation, the altered amino acid(s) may enable binding of the peptide to a major histocompatibility complex class I molecule, or it may project toward the T-cell antigen receptor. 42 Although many clinical trials have shown that patients with high PD-L1 protein expression or a high TMB have a greater response to immunotherapy, some patients with low PD-L1 protein expression or a low TMB may also respond. This may in part be due to tumor heterogeneity and a biopsy specimen from an area of low expression in a tumor that may have high expression in areas not accessed by a small-needle biopsy. [43] [44] [45] As we have already mentioned, another possible reason is that some tumor-specific mutations have higher immunogenicity than others, which means that these mutations can produce the neoantigens that are more easily recognized and would activate the functional T cells. In a case report, Tran et al. described how adopting T-cell transfer therapy targeting mutant KRAS G12D mediated effective antitumor immunotherapy in a patient with metastatic colorectal cancer, 46 in which KRAS G12D is a promising immunogenic mutation that can be designed as a target. The tumor microenvironment is the constitutive element in cancer immunity. A variety of factors contribute to profiling of the microenvironment, such as PD-L1 expression on the TIICs, the levels of many proinflammatory and effector cytokines, the ratio of effector T cells to exhausted T cells, etc. PD-L1 expression on TIICs has been demonstrated to be associated with response to atezolizumab when the SP142 antibody is used 10 and has therefore been adopted in a series of atezolizumab clinical trials as the predictive marker. 6, 11, 47 Several studies have reported that tumor immune-related gene profiling predicted the response to PD-1/PD-L1 blockade. [48] [49] [50] We evaluated the mRNA level of the T-effector and IFN-g gene signature adopted by the POPLAR study employing Affymetrix gene chip and did not find any association with clinical characteristics in early-stage SqCLC.
Data from this study demonstrated that the biomarkers evaluated were not found to be prognostic in patients with early-stage SqCLC who underwent complete resection. However, less than 10% of patients in the cohort demonstrated high expression of PD-L1 at a TPS cutoff of at least 50%. We therefore acknowledge that this low number of patients may have limited the ability to assess the association of PD-L1 expression with survival. No correlation was found between PD-L1 expression on TCs, TMB, and T-effector and IFN-g gene signatures. Patients with a higher TMB have a greater chance of generating neoantigens, which can be recognized by T cells. These patients may therefore have high response rates to immunotherapy when they receive anti-PD-1/PD-L1 therapy and activate effector T cells. Currently, there is no evidence of a direct correlation between TMB and PD-L1 expression and PD-L1 and the T-effector and IFN-g gene signatures. The regulation processes are dynamic and fluctuate over time, as they occur in response to the host antitumor immunity. Few patients in our study (4.6%) had high levels of all biomarkers, indicating that these biomarkers identified distinct subpopulations in SqCLC. These results suggest that composite biomarker detection is needed as a strategy to select patients who may be more likely to benefit from anti-PD-1/PD-L1 immunotherapy. A linear trend was associated with T-effector and IFN-g gene signature expression and PD-L1 expression on TIICs. This finding is similar to the results found in the POPLAR study. Higher levels of T-effector and IFN-g gene signature expression could promote the expression of PD-L1 on TIICs. However, we did not find a significant correlation between PD-L1 expression on TCs and on TIICs. These results support the hypothesis that the expression of PD-L1 is, in general, regulated by different mechanisms in TCs and TIICs. Several intrinsic mechanisms have been identified in TCs as responsible for up-regulating PD-L1 expression, including aberrations of signaling pathways induced by oncogenic event, such as activation of the EGFR, mitogen-activated protein kinase, or phosphoinositide 3-kinase-Akt pathways, 51 elevated expression of signal transducer and activator of transcription 3 and hypoxia inducible factor 1 alpha subunit transcription factors 52 and amplification of PD-L1 and PD-L2 together with Janus kinase 2. 53 Although inflammatory cytokines are also involved in upregulation of PD-L1 expression on TCs, our data showed that the impact of proinflammatory and effector cytokines on TCs may not be as strong as the effect that they have on TIICs in the tumor microenvironment, which is described as an adaptive immune reaction. 10 In summary, this study evaluated the level of three biomarkers related to anti-PD-1/PD-L1 immunotherapy, including PD-L1 expression, TMB, and T-effector and IFN-g gene signature in a cohort with early-stage SqCLC. We found that all of these biomarkers were independent of each other and that independently, none was associated with overall survival of this cohort with newly diagnosed, early-stage SqCLC. Moreover, these results also support the hypothesis that PD-L1 expression is regulated by an intrinsic mechanism on TCs and an adaptive mechanism on immune cells. These findings may be important in the future when evaluating the role of anti-PD-1/PD-L1 immunotherapy in the settings of adjuvant and/or neoadjuvant trials.
